• Stage II-IIIA non-small cell lung cancer; PD-L1-expressing disease, adjuvant treatment as a monotherapy:
    • IV 1680mg every 4 weeks for up to 1 yr OR
      • Started after resection and platinum-based chemo
    • IV 1200mg every 3 weeks for up to 1 yr OR
    • IV 840mg every 2 weeks for up to 1 yr
  • Metastatic non-small cell lung cancer:
    • High PD-L1-expressing disease, first-line treatment as monotherapy:
      • IV 1680mg every 4 weeks OR
      • IV 1200mg every 3 weeks OR 840mg every 2 weeks

 

    • Non-squamous disease, first-line treatment:
      • IV 1680mg every 4 weeks OR
      • IV 1200mg every 3 weeks OR
      • IV 840mg every 2 weeks
    • Progressive disease, monotherapy:
      • IV 1680mg every 4 weeks OR
      • IV 1200mg every 3 weeks OR
      • IV 840mg every 2 weeks
  • First-line treatment in unresectable or metastatic hepatocellular cancer:
    • IV 1680mg every 4 weeks OR
    • IV 1200mg every 3 weeks OR
    • IV 840mg every 2 weeks
  • Unresectable or metastatic melanoma:
    • IV 1680mg every 4 weeks OR
    • IV 1200mg every 3 weeks OR
    • IV 840mg every 2 weeks
  • Unresectable or metastatic alveolar soft part sarcoma:
    • IV 1680mg every 4 weeks OR
    • IV 1200mg every 3 weeks OR
    • IV 840mg every 2 weeks
  • Unresectable locally advanced or metastatic ER/PR-negative HER2-negative breast cancer:
    • IV 1680mg every 4 weeks OR
    • IV 1200mg every 3 weeks OR
    • IV 840mg every 2 weeks
  • Children ≥2 yrs:
    • IV 15mg/kg/dose every 3 weeks
    • Max: 1200mg/dose
  • Injection:
    • 1200mg/20mL
  • Solution should appear colorless to slightly yellow; discard if cloudy, discolored, or particles observed
  • DO NOT shake vial
  • Diluted with 0.9% NaCl only
  • Gently invert diluted solution; do not shake
  • DO NOT give as IV bolus or IV push
  • When administering in combination with chemotherapy, administer atezolizumab before chemotherapy when given on the same day
  • Do not co-administer with other drugs through the same IV line

Monoclonal antibody

It binds to PD-L1 on tumor cells and tumor-infiltrating immune cells, blocking PD-1/PD-L1 pathway-mediated inhibition of anti-tumor immune response, resulting in decreased tumor growth

  • Fatigue
  • Cough
  • Fever
  • Decreased appetite
  • Dyspnea
  • Rash
  • Nausea
  • Constipation
  • Diarrhea
  • Pain
  • Arthralgia
  • Pruritus
  • Hypothyroidism
  • Peripheral neuropathy
  • Pneumonitis
  • Hepatitis
  • Anemia
  • Increased ALT/AST
  • Hypoalbuminemia
  • Hyponatremia
  • Increased creatine
  • Lymphopenia
  • Hypersensitivity to drug or ingredient
  • None restricted

                                   Drug Status

Availability Prescription only
Pregnancy Contraindicated; Can cause fetal harm
Breastfeeding Contraindicated during tx and for at least 5 months after the last dose
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Tecentriq 1200mg/20mL Injection 1’s F.Hoffman La-Roche Roche Kenya